Free shipping on all orders over $ 500

LY573636 (Tasisulam)

Cat. No. M2551
LY573636 (Tasisulam) Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 35  USD35 In stock
10mg USD 60  USD60 In stock
50mg USD 210  USD210 In stock
100mg USD 320  USD320 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY573636 is a novel anticancer agent that induces apoptosis through the intrinsic pathway and has antiangiogenic activity in preclinical models. LY573636 demonstrated activity across a broad range of tumors, including melanoma. LY573636 causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo. LY573636 administered at a targeted C(max) of 420 μg/mL on Day 1 of 21-day cycles demonstrated activity and tolerable toxicity as second-line treatment in malignant melanoma. LY573636 is selectively toxic towards tumor cells over their normal counterparts.

Customer Product Validations & Biological Datas
Source Mol Cancer Ther (2011). Figure 1. LY 573636
Method FACS analysis
Cell Lines Calu-6 and A-375 cell
Concentrations from 200 mmol/L to approximately 200 nmol/L
Incubation Time 72 hours
Results Fluorescence-activated cell sorting (FACS) analysis of Calu-6 and A-375 cell lines showed that tasisulam induced a concentration-dependent increase in 4N DNA
Chemical Information
Molecular Weight 415.11
Formula C11H6BrCl2NO3S2
CAS Number 519055-62-0
Solubility (25°C) DMSO 73 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Kirkwood JM, et al. Cancer. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.

Related Caspase Products

TC11 is a phenylphthalimide derivative and an activator of caspase-9 and CDK1, as well as a degrader of MCL1.TC11 is structurally related to immunomodulatory active molecules. During prolonged mitotic blockade, TC11 induces MCL1 degradation and leads to apoptotic death.


Ac-Ile-Glu-Thr-Asp-pNA is a substrate for caspase-8.


Z-DEVD-AFC is a cell-permeant substrate for caspase-3, which causes a shift in fluorescence uponcleavage of the AFC fluorophore.


Ac-IETD-AFC is a fluorogenic substrate of caspase-8, caspase-3, caspase-10, and granzyme B.


Z-VDVAD-FMK is a special inhibitor of caspase-2.

Abmole Inhibitor Catalog

Keywords: LY573636 (Tasisulam), Tasisulam supplier, Caspase, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.